C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following which the stock rose more than 13%. The Street expects more than 158% upside from the current level, making C4 one of the BBest Rising Penny Stocks to Buy According to Wall Street Analysts.

​Cemsidomide is C4 Therapeutics, Inc. (NASDAQ:CCCC)’s oral drug candidate for relapsed/refractory multiple myeloma, and the data from the phase 1 trial were presented at the European Hematology Association 2026 Congress. Management noted that the drug targets IKZF1, which is a foundational approach in myeloma treatment that also stimulates immune function.

​The data presented covered 73 heavily pretreated patients. Management noted that at the highest dose the drug achieved a 53% overall response rate, a strong result in such a difficult-to-treat population. Notably, responses deepened over time as several patients improved from partial responses to deeper responses, including two achieving MRD negativity. Moreover, the drug was also generally well tolerated, and no discontinuations were recorded.

C4 Therapeutics Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company that is involved in developing novel targeted protein degradation (TPD) therapies.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.